Novel costimulators in the immune gene therapy of cancer.

Journal article

One of the major goals of cancer immunotherapy is the induction of tumour-specific T-lymphocyte responses that will be effective in the rejection of established tumours. The prospects for such therapy rely on the identification of tumour antigens, and although there is persuasive evidence for the presence of such antigens,1,2 the occurrence of the disease does illustrate that the immune system is at least, on some occasions, unable to recognise and destroy these targets. Tumour antigens may b...

Expand abstract

Authors: Galea-Lauri, J; Farzaneh, F; Gäken, J

• Publication status: Published
• Journal: Cancer gene therapy
• Volume: 3
• Issue: 3
• Pages: 202-214
• Publication date: 1996-01-01
• EISSN: 1476-5500
• ISSN: 0929-1903
• Language: English
• Keywords: Immunocompromised Host; Humans; Immunotherapy; Immunoconjugates; Neoplasms; Signal Transduction; Tumor Markers, Biological; Antigens, CD28; Antigens, Neoplasm; Killer Cells, Natural; Models, Immunological; Antigens, CD80; T-Lymphocytes; Antigens, CD; Genetic Therapy; Antigens, Differentiation; Animals; Antigens, Surface; Receptors, Antigen, T-Cell; CTLA-4 Antigen; Cytotoxicity, Immunologic